Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective.
Extended-spectrum beta-lactamase (ESBL)-producing organisms are emerging as a cause of infection in outpatients in many areas of the world. Most of these involve urinary tract infections caused by Escherichia coli harbouring CTX-M types of ESBLs. Risk-factors for such infections include older age and previous use of quinolones and cephalosporins. Oral alternatives for such infections are limited. These organisms may also cause some community-acquired life-threatening infections, such as bacteraemic urinary tract or intra-abdominal infections. Patients with these infections are at increased probability of receiving inappropriate empirical treatment. More studies addressing the risk-factors and therapeutic options for these infections are needed.
D000553:Ambulatory Care; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016470:Bacteremia / Q000453:epidemiology* / Q000382:microbiology; D017714:Community-Acquired Infections / Q000453:epidemiology / Q000382:microbiology; D004755:Enterobacteriaceae / Q000187:drug effects / Q000201:enzymology*; D004756:Enterobacteriaceae Infections / Q000453:epidemiology* / Q000382:microbiology; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology*; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D012307:Risk Factors; D014552:Urinary Tract Infections / Q000453:epidemiology* / Q000382:microbiology; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000145:classification
D000900:Anti-Bacterial Agents; D001618:beta-Lactamases